Literature DB >> 2599716

Characterization of the immunoregulatory properties of thymosin alpha 1 on interleukin-2 production and interleukin-2 receptor expression in normal human lymphocytes.

M B Sztein1, S A Serrate.   

Abstract

Thymosin alpha 1 (T alpha 1) and thymosin fraction 5 (TF5) have been shown to induce lymphocyte maturation and differentiation as well as to modulate mature immune responses to antigens and mitogens. The present study focused on the characterization of the mechanisms involved in T alpha 1 and TF5 enhancement of phytohemagglutinin (PHA)-induced interleukin-2 (IL-2) secretion and interleukin-2 receptor (IL-2R) expression in human mononuclear cells. We provide evidence that TF5 and T alpha 1 modulate an early event(s) during lymphocyte activation by mitogens. A short preincubation period (30 min) of non-adherent cells with thymosins, followed by extensive washing and subsequent exposure to PHA, was sufficient to enhance the production of IL-2 and the expression of IL-2R induced by the mitogen. Furthermore, the concomitant addition of PHA and thymosin during the preincubation period is not necessary for the enhancing effects to occur. We have also studied the role of macrophages on thymosin modulation of these responses. Results presented here indicate that macrophages are not essential for the interaction of thymosins with T-cells. However, macrophages are an absolute requirement during the exposure to the mitogen after preincubation with thymosins for the manifestation of TF5- and T alpha 1-mediated enhancing effects on IL-2 production and IL-2R expression. Human recombinant interleukin-1 beta (rIL-1 beta) was able to replace this macrophage requirement, indicating that production of IL-1 by these cells is a critical event in thymosin modulation of the IL-2 system. Two-color flow cytometric analysis and experiments involving the use of highly purified helper/inducer (Th, CD4+) and cytotoxic/suppressor (Tc, CD8+) T-cell populations indicated that both, Th and Tc cell populations are targets of thymosin activity. These studies provide additional evidence that thymosins play an important role in the modulation of the normal immune response and begin to define the mechanisms underlying T alpha 1 immunoregulatory properties.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2599716     DOI: 10.1016/0192-0561(89)90133-1

Source DB:  PubMed          Journal:  Int J Immunopharmacol        ISSN: 0192-0561


  6 in total

1.  Quantitative analysis of thymosin alpha1 in human serum by LC-MS/MS.

Authors:  C W Tuthill; A Rudolph; Y Li; B Tan; T J Fitzgerald; S R Beck; Y X Li
Journal:  AAPS PharmSciTech       Date:  2000-05-14       Impact factor: 3.246

2.  Thymosin Alpha-1 in Combination with Pegylated Interferon and Ribavirin in Chronic Hepatitis C Patients Who have Failed to Prior Pegylated Interferon and Ribavirin Treatment.

Authors:  Yang Hyun Baek; Sung Wook Lee; Hyun Seung Yoo; Hyun Ah Yoon; Ja Won Kim; Young Hoon Kim; Ha Youn Kim; Sang Young Han
Journal:  Gut Liver       Date:  2007-06-30       Impact factor: 4.519

Review 3.  Roles of thymosins in cancers and other organ systems.

Authors:  Changyi Chen; Min Li; Hui Yang; Hong Chai; William Fisher; Qizhi Yao
Journal:  World J Surg       Date:  2005-03       Impact factor: 3.352

4.  Potential Role of Thymosin-alpha1 Adjuvant Therapy for Glioblastoma.

Authors:  Arno Sungarian; Deus Cielo; Prakash Sampath; Nathaniel Bowling; Peter Moskal; Jack R Wands; Suzanne M de la Monte
Journal:  J Oncol       Date:  2010-01-11       Impact factor: 4.375

5.  The Efficacy and Safety of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Combined With Thymosin in Advanced Non-Small Cell Lung Cancer Patients Harboring Active Epidermal Growth Factor Receptor Mutations.

Authors:  Yongdong Feng; Guangkuo Zhu; Song Lang; Ping Hao; Guanghui Li; Fanglin Chen; Wenlei Zhuo; Yuzhong Duan; Anmei Zhang; Zhengtang Chen; Jianguo Sun
Journal:  Front Oncol       Date:  2021-05-28       Impact factor: 6.244

6.  The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial.

Authors:  Jianfeng Wu; Lixin Zhou; Jiyun Liu; Gang Ma; Qiuye Kou; Zhijie He; Juan Chen; Bin Ou-Yang; Minying Chen; Yinan Li; Xiaoqin Wu; Baochun Gu; Lei Chen; Zijun Zou; Xinhua Qiang; Yuanyuan Chen; Aihua Lin; Guanrong Zhang; Xiangdong Guan
Journal:  Crit Care       Date:  2013-01-17       Impact factor: 9.097

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.